PARP inhibitors can shrink tumors in pancreatic cancer patients with specific mutations
Data presented in a news conference at AACR Annual Meeting ATLANTA - Switching pancreatic cancer patients to the PARP inhibitor rucaparib as maintenance therapy instead...










